| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 43 | 2026 | 1377 | 5.810 |
Why?
|
| Lung Neoplasms | 37 | 2026 | 495 | 5.670 |
Why?
|
| Exercise | 26 | 2026 | 692 | 4.560 |
Why?
|
| Exercise Therapy | 18 | 2026 | 87 | 3.560 |
Why?
|
| Ovarian Neoplasms | 27 | 2023 | 415 | 2.820 |
Why?
|
| Quality of Life | 17 | 2026 | 616 | 2.720 |
Why?
|
| Survivors | 15 | 2023 | 152 | 2.370 |
Why?
|
| Indians, North American | 6 | 2022 | 192 | 2.230 |
Why?
|
| Fatigue | 11 | 2026 | 100 | 2.230 |
Why?
|
| Middle Aged | 79 | 2026 | 12222 | 1.860 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2026 | 133 | 1.760 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2025 | 734 | 1.690 |
Why?
|
| Aged | 57 | 2026 | 8214 | 1.580 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 167 | 1.570 |
Why?
|
| Humans | 142 | 2026 | 43102 | 1.550 |
Why?
|
| Resistance Training | 6 | 2026 | 21 | 1.530 |
Why?
|
| Female | 99 | 2026 | 24698 | 1.520 |
Why?
|
| Health Promotion | 5 | 2023 | 704 | 1.220 |
Why?
|
| Case-Control Studies | 35 | 2025 | 1285 | 1.210 |
Why?
|
| Genome-Wide Association Study | 16 | 2025 | 423 | 1.190 |
Why?
|
| Smoking | 15 | 2024 | 1024 | 1.190 |
Why?
|
| Risk Factors | 38 | 2025 | 3994 | 1.160 |
Why?
|
| Muscle Strength | 4 | 2015 | 37 | 1.150 |
Why?
|
| Male | 61 | 2026 | 23409 | 1.130 |
Why?
|
| Breast Neoplasms | 9 | 2024 | 1723 | 1.050 |
Why?
|
| Adult | 48 | 2026 | 13872 | 0.990 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2025 | 863 | 0.930 |
Why?
|
| Reproductive History | 3 | 2017 | 27 | 0.710 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2021 | 21 | 0.710 |
Why?
|
| Focus Groups | 2 | 2022 | 423 | 0.690 |
Why?
|
| Medical Oncology | 6 | 2025 | 50 | 0.680 |
Why?
|
| Athletic Injuries | 1 | 2021 | 26 | 0.680 |
Why?
|
| Sports | 1 | 2021 | 55 | 0.660 |
Why?
|
| Aged, 80 and over | 14 | 2026 | 2853 | 0.650 |
Why?
|
| Employment | 1 | 2020 | 86 | 0.620 |
Why?
|
| Community-Based Participatory Research | 4 | 2019 | 352 | 0.620 |
Why?
|
| Young Adult | 19 | 2025 | 5080 | 0.610 |
Why?
|
| Immunity | 1 | 2019 | 61 | 0.610 |
Why?
|
| Women's Health | 3 | 2020 | 160 | 0.600 |
Why?
|
| Neoplasms, Glandular and Epithelial | 5 | 2017 | 57 | 0.600 |
Why?
|
| Treatment Outcome | 10 | 2022 | 1604 | 0.590 |
Why?
|
| Interleukins | 1 | 2018 | 40 | 0.580 |
Why?
|
| Postmenopause | 3 | 2020 | 141 | 0.580 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 149 | 0.580 |
Why?
|
| Cost of Illness | 1 | 2019 | 98 | 0.570 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 53 | 0.570 |
Why?
|
| Michigan | 6 | 2025 | 57 | 0.540 |
Why?
|
| Patients | 1 | 2017 | 16 | 0.540 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 449 | 0.520 |
Why?
|
| United States | 27 | 2025 | 5205 | 0.520 |
Why?
|
| Bone Density | 3 | 2012 | 103 | 0.510 |
Why?
|
| Confidentiality | 1 | 2016 | 29 | 0.490 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 22 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 5 | 2021 | 218 | 0.480 |
Why?
|
| Information Dissemination | 1 | 2016 | 66 | 0.470 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2025 | 186 | 0.460 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 14 | 0.460 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 42 | 0.460 |
Why?
|
| Data Collection | 1 | 2016 | 210 | 0.460 |
Why?
|
| Rest | 1 | 2015 | 32 | 0.450 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 269 | 0.450 |
Why?
|
| Community-Institutional Relations | 2 | 2018 | 219 | 0.440 |
Why?
|
| Odds Ratio | 15 | 2019 | 587 | 0.430 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 48 | 0.420 |
Why?
|
| Cohort Studies | 8 | 2024 | 1759 | 0.420 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 374 | 0.410 |
Why?
|
| Prognosis | 9 | 2026 | 861 | 0.410 |
Why?
|
| Motor Activity | 3 | 2016 | 437 | 0.410 |
Why?
|
| Hand Strength | 2 | 2026 | 40 | 0.410 |
Why?
|
| Weight Gain | 3 | 2025 | 139 | 0.400 |
Why?
|
| Pilot Projects | 5 | 2025 | 760 | 0.400 |
Why?
|
| Sleep | 2 | 2026 | 185 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 497 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 15 | 0.380 |
Why?
|
| Body Mass Index | 9 | 2026 | 925 | 0.380 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 706 | 0.370 |
Why?
|
| Hip Fractures | 1 | 2012 | 29 | 0.360 |
Why?
|
| Osteoporosis | 1 | 2012 | 45 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 223 | 0.350 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 21 | 0.340 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 590 | 0.340 |
Why?
|
| Genetic Variation | 5 | 2021 | 430 | 0.330 |
Why?
|
| Carcinoma | 3 | 2016 | 108 | 0.330 |
Why?
|
| Colorectal Neoplasms | 2 | 2026 | 512 | 0.310 |
Why?
|
| Signal Transduction | 1 | 2018 | 2157 | 0.300 |
Why?
|
| Aging | 3 | 2025 | 783 | 0.300 |
Why?
|
| Diet | 4 | 2023 | 826 | 0.280 |
Why?
|
| Delphi Technique | 2 | 2026 | 34 | 0.280 |
Why?
|
| Receptors, Nicotinic | 4 | 2016 | 114 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2023 | 1600 | 0.270 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2019 | 44 | 0.260 |
Why?
|
| Methylphenidate | 2 | 2009 | 56 | 0.250 |
Why?
|
| Recreation | 2 | 2017 | 43 | 0.250 |
Why?
|
| Telomerase | 2 | 2019 | 42 | 0.250 |
Why?
|
| Genome, Human | 3 | 2021 | 144 | 0.250 |
Why?
|
| Arizona | 2 | 2018 | 139 | 0.250 |
Why?
|
| Germ-Line Mutation | 3 | 2015 | 75 | 0.250 |
Why?
|
| Penetrance | 1 | 2025 | 7 | 0.240 |
Why?
|
| Mosaicism | 2 | 2016 | 8 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 291 | 0.240 |
Why?
|
| Physical Fitness | 2 | 2019 | 90 | 0.240 |
Why?
|
| Qualitative Research | 2 | 2020 | 574 | 0.240 |
Why?
|
| Bariatric Surgery | 1 | 2025 | 23 | 0.230 |
Why?
|
| Program Evaluation | 3 | 2022 | 359 | 0.230 |
Why?
|
| Genetic Research | 1 | 2025 | 11 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 180 | 0.230 |
Why?
|
| Haplotypes | 3 | 2021 | 197 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 3 | 2016 | 386 | 0.220 |
Why?
|
| Inflammation | 2 | 2023 | 758 | 0.220 |
Why?
|
| Patient Compliance | 3 | 2026 | 233 | 0.220 |
Why?
|
| Rural Population | 2 | 2025 | 373 | 0.220 |
Why?
|
| Incidence | 7 | 2024 | 1078 | 0.220 |
Why?
|
| Logistic Models | 8 | 2019 | 1009 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2015 | 91 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2002 | 1019 | 0.200 |
Why?
|
| Adiposity | 1 | 2024 | 157 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2025 | 180 | 0.200 |
Why?
|
| Clinical Competence | 1 | 2024 | 156 | 0.200 |
Why?
|
| Life Style | 2 | 2020 | 334 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2019 | 561 | 0.200 |
Why?
|
| Dietary Supplements | 3 | 2017 | 213 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2018 | 10 | 0.190 |
Why?
|
| Students, Nursing | 1 | 2023 | 38 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2025 | 256 | 0.190 |
Why?
|
| Leadership | 1 | 2023 | 86 | 0.190 |
Why?
|
| Interferon-alpha | 1 | 2002 | 43 | 0.190 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 609 | 0.190 |
Why?
|
| Age Factors | 5 | 2026 | 1154 | 0.180 |
Why?
|
| Social Class | 1 | 2024 | 291 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2026 | 590 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2022 | 35 | 0.180 |
Why?
|
| Registries | 3 | 2022 | 437 | 0.180 |
Why?
|
| Marijuana Abuse | 1 | 2023 | 100 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 160 | 0.180 |
Why?
|
| Cultural Competency | 1 | 2022 | 138 | 0.170 |
Why?
|
| Motivation | 1 | 2025 | 513 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 20 | 0.170 |
Why?
|
| Melanoma | 1 | 2002 | 110 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2020 | 142 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 3 | 0.170 |
Why?
|
| Absenteeism | 1 | 2020 | 14 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 14 | 0.170 |
Why?
|
| Body Height | 1 | 2021 | 53 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 29 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 968 | 0.170 |
Why?
|
| Trust | 2 | 2019 | 167 | 0.170 |
Why?
|
| Athletes | 1 | 2021 | 62 | 0.160 |
Why?
|
| Lung | 3 | 2022 | 492 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 139 | 0.160 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 235 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 18 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 143 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 10 | 0.160 |
Why?
|
| RNA Polymerase III | 1 | 2019 | 6 | 0.160 |
Why?
|
| Parity | 2 | 2018 | 59 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2019 | 88 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 40 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2019 | 141 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mental Health | 1 | 2004 | 385 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 8 | 0.150 |
Why?
|
| Lod Score | 3 | 2021 | 13 | 0.150 |
Why?
|
| Glucuronosyltransferase | 1 | 2019 | 29 | 0.150 |
Why?
|
| Mutation | 3 | 2022 | 1177 | 0.150 |
Why?
|
| Research Personnel | 2 | 2021 | 206 | 0.150 |
Why?
|
| Walking | 2 | 2021 | 88 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 215 | 0.140 |
Why?
|
| Health Personnel | 2 | 2019 | 277 | 0.140 |
Why?
|
| Genital Diseases, Female | 1 | 2018 | 38 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2019 | 7 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2019 | 69 | 0.140 |
Why?
|
| Research Design | 3 | 2024 | 385 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 310 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2025 | 719 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 148 | 0.140 |
Why?
|
| Vitamin D | 2 | 2019 | 196 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2015 | 32 | 0.140 |
Why?
|
| Europe | 4 | 2021 | 115 | 0.140 |
Why?
|
| Obesity | 4 | 2024 | 1151 | 0.140 |
Why?
|
| BRCA2 Protein | 2 | 2015 | 50 | 0.140 |
Why?
|
| Health Behavior | 1 | 2022 | 575 | 0.140 |
Why?
|
| Sterilization, Tubal | 1 | 2017 | 6 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 502 | 0.130 |
Why?
|
| Socioeconomic Factors | 4 | 2025 | 1234 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 989 | 0.130 |
Why?
|
| Community Health Services | 2 | 2019 | 206 | 0.130 |
Why?
|
| Mass Screening | 1 | 2022 | 541 | 0.130 |
Why?
|
| Menstruation | 1 | 2017 | 11 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 56 | 0.130 |
Why?
|
| Residence Characteristics | 2 | 2021 | 363 | 0.130 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 106 | 0.130 |
Why?
|
| Ovulation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 107 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 515 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 228 | 0.130 |
Why?
|
| Pedigree | 4 | 2021 | 94 | 0.130 |
Why?
|
| Dairy Products | 1 | 2016 | 34 | 0.130 |
Why?
|
| Genotype | 2 | 2016 | 800 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 17 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 231 | 0.120 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 10 | 0.120 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 23 | 0.120 |
Why?
|
| Phenotype | 2 | 2016 | 780 | 0.120 |
Why?
|
| Powders | 1 | 2016 | 20 | 0.120 |
Why?
|
| Privacy | 1 | 2016 | 7 | 0.120 |
Why?
|
| Vital Capacity | 1 | 2016 | 44 | 0.120 |
Why?
|
| Spirometry | 1 | 2016 | 40 | 0.120 |
Why?
|
| Bioethical Issues | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cultural Deprivation | 1 | 2016 | 3 | 0.120 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 61 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 24 | 0.120 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 21 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2016 | 75 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2015 | 10 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2016 | 65 | 0.120 |
Why?
|
| Medical History Taking | 3 | 2021 | 38 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 333 | 0.120 |
Why?
|
| Protective Agents | 1 | 2016 | 26 | 0.120 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 34 | 0.120 |
Why?
|
| Health Services, Indigenous | 1 | 2016 | 33 | 0.120 |
Why?
|
| Analgesics | 1 | 2016 | 55 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 440 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 245 | 0.110 |
Why?
|
| Selenium | 1 | 2017 | 155 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2017 | 338 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 79 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2016 | 126 | 0.110 |
Why?
|
| Feedback | 1 | 2015 | 56 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 61 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 166 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2026 | 863 | 0.110 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 37 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 53 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2014 | 75 | 0.110 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2014 | 46 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 101 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2026 | 375 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2014 | 121 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2014 | 104 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1092 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 201 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 719 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 259 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 835 | 0.100 |
Why?
|
| Educational Status | 1 | 2014 | 339 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 223 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2012 | 2 | 0.090 |
Why?
|
| Hip Joint | 1 | 2012 | 15 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2011 | 54 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 737 | 0.090 |
Why?
|
| Cytokines | 1 | 2015 | 678 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 249 | 0.090 |
Why?
|
| Public Health | 1 | 2016 | 424 | 0.090 |
Why?
|
| Survival Rate | 2 | 2012 | 355 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2012 | 119 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 25 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 138 | 0.080 |
Why?
|
| Age of Onset | 2 | 2024 | 114 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2026 | 518 | 0.080 |
Why?
|
| Risk | 3 | 2016 | 287 | 0.080 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 420 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 27 | 0.080 |
Why?
|
| Faculty | 2 | 2021 | 105 | 0.080 |
Why?
|
| Population Surveillance | 3 | 2016 | 246 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2010 | 24 | 0.080 |
Why?
|
| Mentors | 2 | 2021 | 145 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2022 | 368 | 0.080 |
Why?
|
| Nursing Assessment | 1 | 2009 | 6 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 76 | 0.080 |
Why?
|
| Child | 3 | 2025 | 3443 | 0.080 |
Why?
|
| Telemedicine | 2 | 2025 | 234 | 0.080 |
Why?
|
| Cognition | 2 | 2023 | 473 | 0.070 |
Why?
|
| Body Composition | 1 | 2009 | 159 | 0.070 |
Why?
|
| Nursing Evaluation Research | 1 | 2008 | 11 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2008 | 37 | 0.070 |
Why?
|
| Valerates | 1 | 2008 | 1 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2026 | 1081 | 0.070 |
Why?
|
| Cachexia | 1 | 2008 | 7 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2009 | 182 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3156 | 0.070 |
Why?
|
| Alcoholic Beverages | 2 | 2018 | 16 | 0.070 |
Why?
|
| Glutamine | 1 | 2008 | 36 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 136 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2026 | 2544 | 0.070 |
Why?
|
| Arginine | 1 | 2008 | 75 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 154 | 0.070 |
Why?
|
| Time Factors | 2 | 2026 | 1857 | 0.060 |
Why?
|
| Decision Making | 2 | 2020 | 249 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 67 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 509 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1063 | 0.060 |
Why?
|
| North America | 2 | 2017 | 85 | 0.060 |
Why?
|
| Asia | 2 | 2017 | 98 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 638 | 0.060 |
Why?
|
| Depression | 2 | 2026 | 863 | 0.060 |
Why?
|
| Minority Groups | 2 | 2021 | 690 | 0.060 |
Why?
|
| Genes, BRCA2 | 2 | 2016 | 12 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2025 | 48 | 0.060 |
Why?
|
| Anxiety | 2 | 2026 | 874 | 0.060 |
Why?
|
| Recurrence | 1 | 2025 | 152 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2025 | 60 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 220 | 0.060 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 263 | 0.060 |
Why?
|
| Adolescent | 3 | 2023 | 6081 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 442 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 48 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1612 | 0.050 |
Why?
|
| Alleles | 2 | 2016 | 352 | 0.050 |
Why?
|
| Australia | 1 | 2024 | 103 | 0.050 |
Why?
|
| Body Weight | 1 | 2026 | 429 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2014 | 206 | 0.050 |
Why?
|
| Insulin | 1 | 2026 | 258 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2026 | 389 | 0.050 |
Why?
|
| Physical Education and Training | 1 | 2023 | 26 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 94 | 0.050 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 70 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 59 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 120 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2002 | 20 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 108 | 0.050 |
Why?
|
| Social Behavior | 1 | 2004 | 161 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1067 | 0.050 |
Why?
|
| School Health Services | 1 | 2023 | 90 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2016 | 403 | 0.040 |
Why?
|
| Environment Design | 1 | 2021 | 32 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2021 | 91 | 0.040 |
Why?
|
| Health Policy | 1 | 2023 | 184 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 82 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2023 | 208 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 199 | 0.040 |
Why?
|
| Schools | 1 | 2023 | 283 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 318 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 575 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Lymphedema | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 48 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 16 | 0.040 |
Why?
|
| Psychometrics | 1 | 2002 | 358 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 240 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 74 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 28 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 78 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 40 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Ovarian Cysts | 1 | 2018 | 3 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 90 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 118 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2018 | 19 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 126 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 89 | 0.040 |
Why?
|
| Overweight | 1 | 2020 | 249 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2019 | 206 | 0.030 |
Why?
|
| Probability | 1 | 2018 | 82 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2019 | 144 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 53 | 0.030 |
Why?
|
| Menarche | 1 | 2017 | 15 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2018 | 42 | 0.030 |
Why?
|
| Students | 1 | 2023 | 626 | 0.030 |
Why?
|
| Endometriosis | 1 | 2018 | 83 | 0.030 |
Why?
|
| Menopause | 1 | 2017 | 64 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 110 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 934 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 162 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 28 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 17 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 163 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 98 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 77 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 445 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 164 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 107 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 400 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2014 | 11 | 0.030 |
Why?
|
| Brain | 1 | 2023 | 1472 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 455 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 146 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 91 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 539 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 294 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 82 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 452 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 983 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 307 | 0.020 |
Why?
|
| Prescriptions | 1 | 2012 | 19 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 1772 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1542 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 327 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 291 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 63 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 518 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 41 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 113 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 234 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 317 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 43 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 64 | 0.020 |
Why?
|